药明康德 (603259)
WuXi AppTec Co., Ltd.
K-Line Chart
No K-line data
Stock Details
1. Key Indicators
- Total Shares(W): 298375.72
- Circulating A-Shares(W): 247328.02
- Earnings Per Share(RMB): 4.2500
- Net Assets Per Share(RMB): 23.9230
- Operating Revenue(W RMB): 3285671.65
- Total Profit(W RMB): 1503706.84
- **Net Profit Attributable to Parent(W RMB) **: 1207551.30
- Net Profit Growth Rate(%): 84.84
- Weighted Return on Equity(%): 19.2600
- Operating Cash Flow Per Share(RMB): 3.8480
- Undistributed Profit Per Share(RMB): 13.1940
- Capital Reserve Per Share(RMB): 10.7013
2. Main Business
The main business covers:
- Integrated platform services for the discovery, research, development, and production of small molecule chemical drugs
3. Company Basic Information
- Company Name: Wuxi AppTec Co., Ltd.
- Listing Date: 2018-05-08
- Industry: Medicine and Healthcare - Medical Services (Tongdaxin Research Industry)
- Address: Registered Address: No. 5 Bridge, Mashan, Binhu District, Wuxi City, Jiangsu Province; Office Address: No. 288 Fute Middle Road, Waigaoqiao Free Trade Zone, Pudong New Area, Shanghai
- Website: https://www.wuxiapptec.com.cn/
- Company Profile: The issuer was established through the overall change of Wuxi AppTec Limited. On February 16, 2017, approved by the board of directors of Wuxi AppTec Limited, all the original shareholders of Wuxi AppTec Limited acted as promoters, converting the audited net assets of Wuxi AppTec Limited as of January 31, 2017, amounting to RMB 3,249,774,976.95, into the share capital of the joint-stock company of RMB 937,787,000, with the remaining portion included in the capital reserve. Wuxi AppTec Limited was wholly transformed into a joint-stock company, and its name was changed to Wuxi AppTec Co., Ltd. On February 17, 2017, Deloitte Touche Tohmatsu verified the capital contribution for the issuer's transformation into a joint-stock company and issued the "Capital Verification Report" (De Shi Bao (Verification) Zi (17) No. 00090). On March 1, 2017, the issuer completed the change registration at the Wuxi Administration for Industry and Commerce and obtained the "Business License" with the unified social credit code 91320200724183068U.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Hong Kong Securities Clearing Company Ltd. | Northbound Funds | 24893.05 | 10.06 |
| 2 | G&C VI Limited | Corporate Entity | 14301.58 | 5.78 |
| 3 | G&C IV Hong Kong Limited | Corporate Entity | 10462.61 | 4.23 |
| 4 | Beijing Zhongmin Yinfu Investment Management Co., Ltd. - Jiaxing Yuxiang Investment Partnership (Limited Partnership) | Asset Management Plan | 8707.46 | 3.52 |
| 5 | G&C V Limited | Corporate Entity | 7310.58 | 2.96 |
| 6 | SSE 50 ETF | Fund | 4778.07 | 1.93 |
| 7 | Huatai-PineBridge CSI 300 ETF | Fund | 4268.15 | 1.73 |
| 8 | G&C VII Limited | Corporate Entity | 3785.33 | 1.53 |
| 9 | Shanghai Houshen Investment Center (Limited Partnership) | Corporate Entity | 3488.20 | 1.41 |
| 10 | Huabao CSI Medical ETF | Fund | 3436.70 | 1.39 |
5. Concept Sectors
- H-Share
- Tongdaxin 88
- Gene Concept
- CXO Concept
- Innovative Drug
- Margin Trading
- Foreign Background
- Large Cap Stock
- High-Performance Stock
- Heavily Held by Funds
- Industry Leader
- High Beta
- Hundred-Yuan Stock
- MSCI Constituent
- Planned Reduction
- Overseas Business
- Heavily Held by Northbound Funds
- Non-Cyclical Stock
- High Receivables
- Special Loans
- SSE 50
- CSI 100
- SSE 180
- Galaxy 99
- Large Cap Growth
- Consumption 100
- SZSE Growth
- CSI 300
- China A80
- 300 Non-Cyclical
- CSI Leaders
- 300 ESG
- MSCI China A50
- SME-ChiNext Index
- Yangtze River Delta
- CSI Buyback
- CSI A50
- CSI A100
Remarks
- Data update date: 2025-11-04
- Data source: Public market information